First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM)

Sponsor

ReST Therapeutics (Industry)

Overall Status

Not yet recruiting

CT.gov ID

NCT05921929

Collaborator

(none)

Enrollment

Location

Arm

Anticipated Duration (Months)

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The goal of this First-In-Human (FIH) trial is to learn about safety and PharmacoKinetics (PK) in healthy adult volunteers. The main questions it aims to answer are:

What is the safety of single ascending doses of the FluoroEthylNorMemantine (FENM)?
What is the PK profile of single ascending doses of the FENM in human?
What is the preliminary exploratory time course of Brain Disease Neurotrophic Factor (BDNF) plasmatic levels of single ascending doses of the FENM? Participants will receive one single oral dose of FENM.

Condition or Disease	Intervention/Treatment	Phase
PTSD Alzheimer Disease Brain Diseases Neuro-Degenerative Disease Major Depressive Disorder Treatment Resistant Depression	Drug: Fluoroethylnormemantine (FENM)	Phase 1

Study Design

Study Type:

Interventional

Anticipated Enrollment :

36 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Other

Official Title:

Safety and Pharmacokinetics of a Novel NMDA Receptor Antagonist Against Brain Related Diseases in Healthy Adult Volunteers: First-in-human, Phase I, Single Dose-escalating, Open Label Study

Anticipated Study Start Date :

Sep 1, 2023

Anticipated Primary Completion Date :

Sep 1, 2024

Anticipated Study Completion Date :

Sep 1, 2024

Arms and Interventions

Arm	Intervention/Treatment
Experimental: One single oral dose per participant	Drug: Fluoroethylnormemantine (FENM) Single ascending oral dose administration according to the following scheme: 20, 40, 80, 120-160, 200-240, 260-320mg/kg (six dose levels). The three upper dose levels to be administered (120-160, 200-240, 260-320mg/kg) will be precisely determined with the data collected at the end of the first three dose levels administered.

Arm

Intervention/Treatment

Experimental: One single oral dose per participant

Drug: Fluoroethylnormemantine (FENM)

Single ascending oral dose administration according to the following scheme: 20, 40, 80, 120-160, 200-240, 260-320mg/kg (six dose levels). The three upper dose levels to be administered (120-160, 200-240, 260-320mg/kg) will be precisely determined with the data collected at the end of the first three dose levels administered.

Outcome Measures

Primary Outcome Measures

Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [From single dose administration to the end of the study follow-up (2 weeks later)]

Secondary Outcome Measures

To assess maximum plasma concentration [Cmax] [At pre-dose and at 2, 4, 6, 8, 10, 12, 24, 48, 96, 189, 264 and 336hours post-dose]
To assess time to Cmax [Tmax] [At pre-dose and at 2, 4, 6, 8, 10, 12, 24, 48, 96, 189, 264 and 336hours post-dose]
To assess minimum concentration within the dosing interval [Cmin] [At pre-dose and at 2, 4, 6, 8, 10, 12, 24, 48, 96, 189, 264 and 336hours post-dose]
To assess last observed plasma concentration [Clast] [At pre-dose and at 2, 4, 6, 8, 10, 12, 24, 48, 96, 189, 264 and 336hours post-dose]
To assess time of the minimum concentration [Tmax] [At pre-dose and at 2, 4, 6, 8, 10, 12, 24, 48, 96, 189, 264 and 336hours post-dose]
To assess area under the plasma concentration-time curve from 0 to the end of the dose interval [AUC 0-tau] [At pre-dose and at 2, 4, 6, 8, 10, 12, 24, 48, 96, 189, 264 and 336hours post-dose]
To assess area under the plasma concentration-time curve from dosing (time 0) to the time of last measured concentration [AUC 0-last] [At pre-dose and at 2, 4, 6, 8, 10, 12, 24, 48, 96, 189, 264 and 336hours post-dose]
To assess total area under the plasma concentration-time curve from dosing (time 0) taken to the limit as the end time becomes arbitrarily large (infinity) [AUC 0-∞] [At pre-dose and at 2, 4, 6, 8, 10, 12, 24, 48, 96, 189, 264 and 336hours post-dose]
To assess terminal half-life, apparent elimination half-life [T1/2] [At pre-dose and at 2, 4, 6, 8, 10, 12, 24, 48, 96, 189, 264 and 336hours post-dose]
To assess apparent oral clearance [CL/F] [At pre-dose and at 2, 4, 6, 8, 10, 12, 24, 48, 96, 189, 264 and 336hours post-dose]
To assess apparent volume of distribution [Vz/F] [At pre-dose and at 2, 4, 6, 8, 10, 12, 24, 48, 96, 189, 264 and 336hours post-dose]
To assess preliminary exploratory time course of Brain Disease Neurotrophic Factor plasmatic levels of single ascending doses of the FENM [At pre-dose, at Cmax (estimated at 6-8hours post-dose) and at 48, 72 and 264hours post-dose]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 45 Years

Sexes Eligible for Study:

Male

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

willing and able to sign written informed consent,
Body Mass Index (BMI) of 17.5 to 30.5 kg/m2, a total body weight >65 kg,
efficient contraceptive mean,
no major psychiatric disorder per the Mini-International Neuropsychiatric Interview (MINI) questionnaire,
normal laboratory tests results, arterial Blood Pressure/pulse rate, 12-lead Electrocardiogram recording.

Exclusion Criteria:

evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, allergic disease including drug allergies, or other severe acute or chronic medical or psychiatric condition or laboratory abnormality,
history of febrile illness within 5 days prior to administration,
any condition possibly affecting drug absorption,
using of prescription drugs, vaccine, routine or as needed consumption of medications or herbal supplements,
having positive serology, positive urine test for drugs of abuse, a general medical or psychological condition or behavior, including current substance dependence or abuse,
history of drug or alcohol abuse within 1 year before screening,
consuming currently of nicotine containing products, any food or any beverage containing grapefruit or grapefruit juice within 48 h prior to administration,
having blood donation or loss of significant amount of blood within 2 months prior to study.